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In this research, a model system for studying the effects  of the toxic metabolite, 
methylglyoxal, was created using Chinese Hamster Ovary (CHO)  cells which produce tissue 
plasminogen activator (t-PA). The human gene for glyoxalase I was subcloned into an 
inducible mammalian expression vector. This vector was then used to create three stable 
CHO integrants, two control and one putative glyoxalase I producing cell lines. The CHO 
clones were characterized for the production of glyoxalase I using both SDS-PAGE gels and 
glyoxalase activity assays. In addition, the cell lines were evaluated to determine the levels of 
free methylglyoxal produced. The putative glyoxalase producer showed higher levels of 
glyoxalase I activity than the parent cell line and produced a unique protein band at the 
correct molecular weight. They also had a significantly lower level of free methylglyoxal than 
either of the two control cell lines. These cells can now be used as a tool to determine the 
specific effect of methylglyoxal on the yield and quality of tissue plasminogen activator 
produced. 
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Chapter 1: Introduction 
With the advent of recombinant DNA technology, the use of genetically engineered 
organisms to produce therapeutic proteins has become an important biomedical approach. 
More recently, the use of mammalian cells has lead to the ability to produce highly complex 
proteins which bacteria are unable to process. Unfortunately, using mammalian cells to 
produce biopharmaceuticals presents several problems. Such cells are slower growing, more 
difficult to keep sterile, and require highly defined media. The process of optimizing 
mammalian cell growth on a large-scale is an important biological engineering problem. 
Since these cells have complex metabolic pathways, it is often difficult to isolate 
factors that interfere with growth. Toxic by-products of growth are a category of 
compounds known to decrease cellular productivity. The most well studied toxic by-
products are ammonium and lactate, however there is evidence to suggest that other 
metabolites may interfere with growth. 
The following work involves the creation of a model cell line to study a specific toxic 
metabolite, methylglyoxal. This compound is produced during normal cellular respiration 
through several different pathways. A Chinese Hamster Ovary (CHO) cell line which 
produces tissue plasminogen activator (t-PA) was chosen for the model, due to the industrial 
relevance. CHO cells are used routinely for the production of commercially important 2 
proteins. Tissue plasminogen activator was one of the first such proteins produced  using 
large-scale mammalian cell culture. It is a well characterized protein with commercially 
available antibodies. 
In order to specifically study the effects of methylglyoxal, one of its degradation 
enzymes, glyoxalase I was cloned into the CHO cell line under the expression of an 
inducible promoter. Cell extracts from clones and control cell lines were characterized  for 
the production of glyoxalase I and methylglyoxal. 3 
Chapter 2: Literature Review  
2.1  Toxic Metabolites 
Mammalian cell cultures are used primarily for the production of therapeutic 
proteins and viral vaccine antigens. Optimizing product yield in these cultures is a 
complex engineering problem. Product yield is dependent on maintaining high-
density cell cultures for long time periods. Unfortunately, these conditions are 
conducive to the production of toxic metabolites, which then inhibit the ability of 
cells to produce proteins efficiently. More importantly, toxic metabolite 
accumulation can interfere with the ability of cells to produce a consistent protein 
product, i.e., toxic metabolites can cause protein microheterogeneity (Andersen and 
Goochee, 1995; Hansen and Emborg, 1994). Protein microheterogeneity can affect 
the efficacy and consistency of the drug product and is a major concern during the 
lot to lot production of biologicals. 
Ammonium and lactate are currently believed the major inhibitory 
compounds produced by mammalian cells in industrial cell culture. Ammonium is 
produced as a by-product of glutamine catabolism, while lactic acid is produced as a 
result of glucose metabolism through the glycolytic pathway (Glacken et al., 1985). 
Ammonium interferes with protein glycosylation, thought to be the result of an 
increase in intracellular pH (Andersen and Goochee, 1995). Lactic acid causes an 
decrease in the pH of the culture medium which reduces the buffering capacity, 
inhibiting cell growth (Glacken et al.  1985). Ammonium levels can be controlled by 4 
reducing the amount of glutamine in the culture media, while lactic acid levels can he 
reduced by lowering the amount of glucose fed. Both of these can be accomplished 
by carefully controlling the rates of these nutrients in fed-batch culture (Glacken et 
al.,  1985). 
Recent work suggests that another lesser-known compound may also have a 
role in culture inhibition (Chaplen et al., 1996a). Methylglyoxal is an a-ketoaldehyde 
produced as a by-product of cellular respiration. This toxic metabolite binds and 
modifies both proteins and nucleic acids under physiological conditions (Thornalley 
1996). Methylglyoxal is found in high levels in CHO cells grown in culture, and 
evidence suggests that it may play a role in decreasing cell viabilities (Chaplen et al. 
1996a; 1998). 
2.2  Methylglyoxal Metabolism 
Methylglyoxal is produced both enzymatically and non-enzymatically in 
mammalian systems (Figure 1). The major route for methylglyoxal production is 
non-enzymatic phosphate limitation from the enediol intermediate that occurs 
during the interconversion of dihydroxyacetone phosphate and glyceraldehyde 3-
phosphate (Richard, 1984; 1991). In red blood cells, methylglyoxal production rates 
have been measured at approximately 120.1M/day (Thomalley, 1988), representing 
approximately 0.1% of the total glycolytic flux (Thomalley 1996). Evidence suggests 
that production rates in transformed cell lines are far higher (Chaplen et al., 1996a). 
Intracellular methylglyoxal is a complex mixture of free and bound forms. As much 
as 1000-fold more methylglyoxal is associated with cellular structures, such as protein 
and nucleic acids (Chaplen et al., 1998). The high affinity of methylglyoxal for 5 
protein and nucleic acids means that even a small absolute increase in measured free 
methylglyoxal may have a significant impact effect on the production and quality of 
recombinant protein products. 
2.3  Methylglyoxal Modification of Protein and DNA 
Methylglyoxal is known to modify both proteins and DNA under 
physiological conditions (Thomalley 1996). Reversible and irreversible protein 
modification occur at arginine, lysine and cysteine residues. Glycosylamine 
derivatives are formed with arginine and lysine residues, with arginine as the primary 
modification target at low levels ( <5p.M) of methylglyoxal (Thornalley, 1996). 
Cysteine residues interact to form hemithioacetals. These reactions are highly 
reversible (Lo et.al, 1994). It has been shown by several groups that > 99°0 of the 
intracellular methylglyoxal is bound to molecules, primarily proteins. (Lo et al., 1994, 
Chaplen, 1998). 
Methylglyoxal modification targets proteins for degradation pathways by 
creating compounds similar to advanced glycosylation end products (AGE) 
(Westwood and Thornalley 1995). These AGE like adducts compete for the AGE 
receptor and are taken in by macrophages and destroyed. Since many enzymes have 
arginine and cysteine in their active sites, it is likely that methylglyoxal modification 
of these residues would cause a decrease in enzyme function (Chaplen, 1998 ). This 
may include enzymes responsible for protein processing resulting in  variation of a 
protein product. Signal sequences usually include a lysine and arginine (Alberts el al., 
1994). 6 
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Figure 1. Methylglyoxal Metabolism 7 
Modification of these residues could cause aberrant protein targeting within the cell. 
In addition to these effects, steric hindrance caused by methylglyoxal adducts may 
inhibit the proper folding of proteins. 
Methylglyoxal also reacts with DNA, primarily at guanine residues 
(Krymkiewicz 1973). Relatively low levels of methylglyoxal (< 5[IM) induced DNA 
single strand breaks and DNA-protein crosslinks (Brambilla  et al.  1985). At 
physiological concentrations, it can modify unprotected plasmid DNA and cause 
gene mutation (Papsoulis  et al.,  1995). At higher concentrations (>200p,M)  it can 
and induce sister chromatid exhanges (Tucker et al.,  1989).  Most of these studies, 
however, were done with relatively impure solutions of methylglyoxal, and therefore 
need confirmation using high purity methylglyoxal (Thornalley, 1996). 
2.4  Methylglyoxal Detoxification 
There are two major pathways for the degradation of methylglyoxal. The 
primary pathway, the glyoxalase system, consists of the enzymes glyoxalase I and 
glyoxalase II. Glyoxalase I converts hemithioacetal, formed when methylglyoxal 
combines non-enzymatically with reduced glutathione (GSH), to S-D-
lactoylglutathione. Glyoxalase II then converts this compound to D-lactate. A 
second pathway utilizes the enzyme aldose reductase to convert methylglyoxal to 
acetol and then to L-1,2- propanediol. (fhornalley, 1995). Both pathways are 
outlined in Figure 1.  Though both systems detoxify methylglyoxal, it is estimated 
that 10-40 fold more is detoxified by the glyoxalase pathway (Thornalley, 1996). 8 
2.5  Effect of Methylglyoxal on Animal Cells in Culture 
In animal cells grown in culture, glucose, glutamine and fetal bovine serum 
levels have been shown to have an effect on intracellular methylglyoxal 
concentrations (Chap len et al. 1996a). Previous studies using the Pseudomonas putida 
gene for glyoxalase I have shown that over expression of this enzyme can lower 
cellular levels of methylglyoxal. When cells expressing this bacterial enzyme were 
tested in colony forming assays, they showed an increased ability to survive over the 
wild type cells under conditions which induce high levels of methylglyoxal (Chaplen 
et al,1996a). These findings, taken in conjunction with the evidence that 
methylglyoxal modifies DNA and protein, support the theory that decreasing 
endogenous methylglyoxal levels may increase cellular growth rates and possibly 
productivity. 9 
Chapter 3: Materials and Methods 
3.1  Subcloning Human Glyoxalase I 
3.1.1  Transformation 
The 622 by gene for Human Glyoxalase I was isolated from a plasmid 
provided by a group at the Fox Chase Cancer Center (Ranganathan et al. 1993) and 
cloned into the EcoRI site of the pIND plasmid. The original glyoxalase I 
containing plasmid, pIND, and pVgRXR plasmids (See Maps in Appendix) were 
transformed as follows into competent JM109 E.coli cells (Promega). 10 ml Falcon 
tubes were pre-chilled on ice and SOng of each plasmid was added to the tube. For a 
control, TE alone was used. Competent cells were thawed on ice, 50111 was added to 
each tube, and the tubes were then placed on ice for 10 minutes. Cells were heat 
shocked at 42 °C for 45 seconds, and immediately placed on ice for 2 minutes. Next, 
900pt1 of SOC broth was added to each tube, with the exception of the pVgRXR 
which received 900111 of low salt LB media. After mixing, the cells were incubated 
shaking at 37 °C for one hour. The transformed cells were dilution plated on to LB 
ampicillan plates (501.1g/m1), with the exception of pVgRXR, which was plated on to 
low salt LB plates containing 25µg /ml Zeocin. Plates were incubated overnight at 
37 °C and colonies were picked for mini preps from 1:100 dilution plates. Mini prep 
plasmids prepared using the alkaline lysis method (Maniatis et al., 1989) were then ran 
on 1% 'I BE agarose gel and compared to original plasmids for size. 10 
3.1.2  Restriction Digests 
All three plasmids were grown in 50m1 cultures and isolated using the 
Invitrogen S.N.A.P. Midi Prep Kit. The pIND and gloxalase I containing plasmids 
were then cut with EcoRI at 37° C for 4 hours. Digested DNA was run out on a  1°/0 
agarose gel and 622 by fragment containing the glyoxalase I gene was  excised from 
the gel for further purification using the GENE CLEAN kit (1310 101). The 
linearized pIND plasmid was treated with calf intestinal alkaline phosphate (CIAP 
Promega Catalog #M1821) to remove the 5' phosphate groups and purified using 
GENE CLEAN kit. 
3.1.3	  Transformation 
The purified fragment was then ligated to 10Ong of purified CIAP treated 
vector overnight at 4 °C. The ligation was transformed into competent JM109 cells 
as previously described. Twelve colonies were picked and grown up for mini preps. 
After digestion with EcoRI to release the fragment, ten appeared to be the same. 
These ten were digested with PstI and XbaI to determine the orientation of the 
fragment. The restriction pattern showed two distinct plasmids, though it was 
impossible to determine the orientation given the restriction maps. One of each 
pattern was picked for sequencing. 
3.1.4	  Sequencing 
The plasmids were grown up and isolated using Promega Wizard Prep. The 
24 by forward primer supplied with the ecdysone cloning kit from Invitrogen was 
resuspended to 5pmo14.1.1. Plasmids (600ng/51.1.1) and primer (5.i1 of 5pmo1/11.1) were 11 
given to the central research facility to sequence using fluorescent sequencing. 
Sequenced plasmids were grown up and isolated using the S.N.A.P midi prep 
method for later use in transfection. 
3.2  Dilution Cloning 
CHO 1-15500 Cells (ATCC #F 14472) were thawed and diluted 1:15 into 
Hams F12 media containing 10% fetal bovine serum and 500 nM methotrexate. 
Methotrexate is needed to maintain the t-PA gene as it was cloned using the DHFR 
system. 
Cells were maintained in this media and then slowly weaned to DMEM 
(Irvine Scientific Cat# 2043) containing 10% FBS, and 500nM methotrexate. Cells 
were then maintained for several passages before dilution cloning as follows. A T75 
flask at 80% confluence was washed twice with PBS, trypsinized and counted using a 
hemocytometer. Cells were then diluted in DMEM into a 48 well tissue culture dish 
to give approximately 1 cell per well. Cells were then grown to confluence to be 
tested for tPA production. 
3.3  Toxicity Testing 
CHO cells were plated out in 60 mm dishes and grown to about 50% 
confluence. Cells were fed media with 0, 50, 125, 250,500, 750, and 1000 µg /ml of 
G418 (Sigma). The same concentrations were used in separate dishes for Zeocin. 
Media was changed every 4 days and new drug was added for about 2 weeks. Total 
killing was seen with G418 at 750µg /m1 and near total killing was seen with Zeocin 
at 1000R/ml. 12 
3.4  Transfection 
3.4.1  Stable Transfection 
Confluent 150 mm dishes were split 1:3 one day before the transfection. 
Cells were fed 20mls fresh media 2 hours before the addition of DNA. The 
following four transfections were used: no DNA, forward orientation of the 
glyoxalase I clone, reverse orientation of the glyoxalase I clone, and pIND. All 
plates were transfected with 15ug of the respective plasmid as well as 15111 of the 
helper plasmid pVgRXR using the Calcium Phosphate method (Ausubel et al., 1992). 
The media was changed 10 hours after the transfection, and cells were split 1:4 into 
new dishes 2 days later. At that time, all cells were fed media containing 1mg/m1 
G418 and 0.75mg/m1 Zeocin. The media was changed after 4 days and after 8 days 
fresh media was added containing only 0.5 mg/ml of both G418 and Zeocin. After 
approximately 2 weeks, colonies were picked using sterile cloning rings and 
transferred into 48 well dishes. This process was repeated a second time to obtain 
the forward orientation clone. 
3.4.2  Transient Transfection 
The transient transfection was used to look for expression of glyoxalase I 
while the stable transfectants were being expanded. For this experiment, four 
150 mm dishes were used for both the forward orientation clone and the reverse. 
The calcium phosphate method was used and fresh media was added 14 hours after 
the transfection. At that time, the two plates of each clone were induced with 13 
6.25 1..iM Ponasterone A. Cells were harvested, resuspended in PBS and lysed by 
sonicating 3 times for 5 seconds on ice. Samples were spun at 14,000 x g and the 
supernatant was removed and frozen at 20°C 
3.5  Southern Blot 
3.5.1  Genomic DNA Isolation 
Once clones were expanded, the cells were grown to confluence in a T75 
flask and two thirds of these cells were used to isolate genomic DNA using 
Promega's Genomic DNA prep kit. For each clone, two microcentrifuge tubes were 
processed as follows. Cells were trypsinized and harvested into a 1.5 ml 
microcentrifuge tube and centrifuged at 14,000 x g for 10 seconds to create a pellet. 
The supernatant was removed leaving behind the cell pellet plus about 251_11 of 
residual liquid. Pellets were then washed with 200 p.I of PBS, supernatant was 
removed as before, and the pellet was vortexed. Next, 600111 of Nuclei Lysis 
Solution was added and cells were pipetted up and down until no cell clumps 
remained. Rnase Solution was added (3p.1) to the nuclear lysate and the sample was 
mixed by inversion, then incubated at 37 °C for 30 minutes. Following incubation, 
the sample was cooled for 5 minutes at room temperature. Then, 200p1 of Protein 
Precipitation Solution was added and samples were vortexed vigorously for 20 
seconds and chilled on ice for 5 minutes. The protein was pelleted by centrifugation 
at 14,000 x g for 4 minutes. The supernatant was removed and added to a clean 
microcentrifuge tube containing 600111 of room temperature isopropanol. Tubes 14 
were mixed by inversion and then spun for 1 min at 14,000 x g to pellet the DNA. 
Pellets were washed with 700/0 ethanol and allowed to air dry for 15 minutes. Pellets 
were resuspended in 1040 DNA Rehydration Solution and incubated at 65 °C for 1 
hour before storage at 20 °C. 
3.5.2	  Probe 
The DIG DNA Labeling kit (Boehrigner Manheim #1175033) using approximately 
1.51.1g of the pIND and pVgRXR plasmids was used to make the probes as follows. 
The plasmids were diluted to 15µl with dH20 and boiled for 10 minutes to denature 
the DNA. Tubes were then chilled on ice for 5 minutes and the following were 
added; 211.1 of hexanucleotide mix, 21.11 of dNTPs, and lµ1 of Klenow. Samples were 
spun briefly and incubated at 37 °C for 2 1/2 hours. 
3.5.3	  Transfer 
Genomic DNA isolated from clones and was digested with EcoRI and then 
loaded on to a 1% agarose gel with DIG labeled markers and pIND and pVgRXR 
plasmids as controls. The gel was run at 75 volts for 30 minutes and overnight at 30 
volts. The gel was transferred onto a .45 micro Nylon membrane using the non-
denaturing Southern Blot protocol (Ausubel pp. 24-25). After overnight transfer, the 
membrane was removed, UV crosslinked, and allowed to air dry. The blot was then 
cut in half, as it was a duplicate gel, with the exception of the plasmid control for 
each half. 15 
3.5.4  Hybridization and Detection 
For Prehybridization and Hybridization, DNA easy hybridization solution 
from Boehringer Mannheim (Cat # 1796895) was used. The two membranes were 
sealed into plastic bags with 15mls of prehybridization solution. The blots were 
incubated at 37°C for 2 ',/2 hours. The bags were cut and the prehybridization 
solution was drained. To each bag, 10mls of easy hybridization solution was added. 
The probes were boiled for 5 minutes and placed on ice before they were added to 
blots containing the corresponding plasmid control. The bags were then sealed and 
hybridized overnight at 37°C. Blots were washed two times for 5 minutes at room 
temperature in 2X SSC; 0.1% SDS , and two times for 15 minutes at 68°C in 0.1X 
SSC; 0.1%SDS. 
Blots were then washed following directions in the Boehringer Mannheim 
DIG Wash and Block Buffer Set (Cat #1585762). Briefly, membranes were washed 
for 1 min in lx washing buffer and then blocked for 60 minutes in 100mls lx 
blocking solution. Anti-digoxigenin-AP conjugate antibody (BM Cat# 1093 274) 
was diluted in 1:10000 in blocking solution. Blots were then incubated with gentle 
agitation in 20mls of antibody solution. Following the incubation, the membranes 
were washed two times in lx washing buffer and then equilibrated for 5 minutes in 
20 mls detection buffer. The chemiluminescent substrate, CSPD (BM Cat # 1655 
884) was diluted in detection buffer. Blots were then transferred to sealed plastic 
bags with 2mls of the CSPD solution for 5 minutes. The excess was drained and the 
membranes were damp sealed into plastic bags and incubated at 37°C for 10 minutes 
before exposure to X-ray film. 16 
A second Southern was done as above with the exception of using CHO cell 
DNA as a control and the hybridization was done at 42°C. 
3.6  Induction of Glyoxalase I 
To induce glyoxalase expression, a T175 flask was split into four 150 mm 
dishes. Cells were allowed to grow for 24 hours to approximately 80% confluence. 
This was done for both the forward orientation CHO clones and for the CHO cell 
line alone as a control. Cells were induced with Ponasterone A at 0, 1, 5, and 10p.M 
concentrations for 24 hours. The spent media was then harvested and frozen at 
20° C. The cells were trypsinized, washed and sonicated in 500 Ill as described 
earlier. Cell lysates were spun at 14,000 x g to pellet the debris and frozen at 20° C. 
3.7	  SDS Polyacrylamide Gel Electrophoresis 
For all protein gels, 12% ready gels were used with the mini Protean II unit, 
both from BioRad.  All samples were diluted 1:1 in 2x sample buffer ( Laemmli) and 
heated to 95°C for 5 minutes before loading on the gel. Kaleidoscope prestained 
standards were used standards were used for molecular weight markers. (BioRad Cat 
# 161-0324).  All gels were run at 150V for approximately 40 minutes in lx running 
buffer (Tris:Gylcine:SDS). Gels were then stained in a solution containing 40'0 
methanol, 10% acetic acid, and 0.1% Coomassie blue. Destaining was done using 
several changes of a 40% methanol, 10°/0 acetic acid solution. Gels were then 
pressed between two sheets of plastic and allowed to dry before photographing. 17 
3.8  Total Protein Assay 
All total protein assays were done using the BioRad kit following the 
Bradford method. Briefly, the BSA standard protein was reconstituted in 20m1 
milliQ dH2O to a concentration of 1.46 mg/ml. This stock solution was used to 
make standard dilutions of 0.2, 0.4, 0.6, and 0.8 mg/ml. Various dilutions of cell 
lysates or media were used for sample protein assays. In all cases, dilutions were 
brought up to 100p1, and added to small plastic test tubes. Next, 5 ml of dye (diluted 
1part dye to 4 parts dH2O) was added and each tube was vortexed. Samples were 
allowed to sit for 40 to 50 minutes at room temperature before their absorbance was 
measured at 595 nm. 
3.9  t-PA Assay 
The t-PA activity assay was developed for use in further studies. The 
protocol is modification of several protocols (Drapier et al., 1979; Lin et al. 1993). 
Spent media was measured for t-PA activity by incubation with a cocktail containing 
0.13 tlIVI plasminogen, 0.711M S2251 (Val-Leu-Lys-paranitroaniline)  and 0.6pM 
Fibrin. The buffer for reaction is 0.1M Tris -Cl, 1% Tween 20, pH 7.5. The 
plasminogen is cleaved by the fibrin activated t-PA to produce plasmin. Plasmin 
reacts with the synthetic peptide S2251 to produce nitroanaline, which has a 
maximum absorbance at 412nm. The dilution clones were assayed and compared 
for relative t-PA activity. 18 
3.10  Glyoxalase I Assay 
Cell lysates were assayed for glyoxalase I activity using the  
spectrophotometric method of Thornalley (1988).  
3.11	  Methylglyoxal Assay 
Samples were assayed for free and total methylglyoxal using HPLC as 
described in Chaplen et al. (1996c). Samples represent media harvests from 
individual dishes induced overnight with 5pM ponesterone A. Nine samples were 
used for each clone and the data was analyzed using the Mann-Whimey Rank Sum 
Test. 19 
Chapter 4: Results  
4.1  Glyoxalase I Clone 
The cDNA for human glyoxalase I from the colon was obtained from 
Sulabha Ranganathan (Ranganathan et al. 1993) and cloned into a pIND plasmid as 
described in Chapter 3. Clones were isolated and putative glyoxalase I constructs 
isolated for characterization through restriction digest, gel electrophoresis and 
subsequent sequencing of the cDNA insert. 
Two distinct patterns were revealed following a digest of putative glyoxalase 
I constructs. Subsequent sequencing revealed that the patterns were representative 
of forward and reverse orientation clones of the glyoxalase I gene (g/o1). The 
sequence of the forward (correct) orientation clone was compared to the published 
sequence of human gloI (Ranganathan et al. 1993). This comparison revealed that 
there was a single base pair difference (A rather than C) between our clone and the 
published gene sequence at position 332, resulting in an amino acid change from 
alanine to glutamic acid. The original plasmid was sequenced to determine whether 
this mutation had occurred during the cloning process and was found to contain the 
same point mutation. Careful examination of the literature determined that this was 
in fact another isoform of human glyoxalase I. (Ridderstorm and Mannevick; Kim et 
al. 1995). The isoform is a fully functional enzyme, and the decision was made to 
move forward with the creation of the cell lines. 20 
4.2  CHO Cell Line 
4.2.1  Transient Transfection 
Both forward and reverse orientation constructs were tested through 
transient expression in COS cells. SDS-PAGE gels were used to determine if 
glyoxalase I was being expressed. There were no differences in the protein patterns 
of the reverse and forward orientation clones (Data not shown). 
4.2.2  Stable Transfection 
Three plasmids were used to create stable cell lines, the pIND plasmid, and 
the forward and reverse orientations of the glyoxalase I gene cloned into the pIND 
plasmid. The cells were selected using G418 and Zeocin, expanded and analyzed for 
integration of the plasmids and expression of glyoxalase I. These cells grew much 
more slowly than the parent cell line. 
4.3  Southern Blot 
The Southern blot was done to confirm that our constructs and the control 
plasmid (pIND) were chromosomally integrated. Blots were probed with both 
pIND and pVgRXR, the helper plasmid. The first Southern probed with pIND 
(Figure 2), showed a common band across all lanes, in addition to multiple bands in 
2 of the pIND control cell line lanes. The pVgRXR probed Southern showed 2 
common bands across all lanes and multiple bands in the second pIND control lane. 
Since the first Southern was missing a critical control, the CHO parent cell line 
DNA, the experiment was repeated. The second Southern revealed the same 21 
common band in all lanes. Based on the provided plasmid map, the pIND plasmid 
contains no mammalian sequences. Thus, it is likely that the multiple cloning region 
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Figure 2. Southern Blot Probed with pIND. 22 
4.4  SDS-PAGE 
Cell lysates were run out on 12% SDS-PAGE gels to determine glyoxalase I 
protein expression. The forward glyoxalase I clone was compared to the CHO cell 
line under four different levels of induction as shown in figure 3. For both 
glyoxalase I clones, there was a band running slightly above the 18 kD molecular 
weight marker which was not present in the CHO control. This band likely 
represents glyoxalase I, which runs at approximately 21 kD on SDS-PAGE gels 
(Ranganathan et al., 1993). 




Figure 3. SDS PAGE gel of Control and forward orientation clone 
cell lysates under varying levels of induction. 
18 23 
The band was present in all lanes of the clone, even the non- induced cells. 
It was difficult to tell whether there was any difference in the band intensity under 
the different levels of induction due to the variation in total protein loaded. Later 
gels, normalized to total protein, showed roughly similar levels of protein in all four 
lanes. It is also noteworthy that given total protein concentrations, there is roughly 
2- fold more protein loaded in several of the control lanes. This further strengthens 
the argument that the band is unique to the clones. 
Table 1. Total Protein Concentrations of Cell lysates in mg/ml. 
Cell line  0 1.1M inducer  1µM  5µM  10 pM 
CHO  2.2  2.0  1.8  1.4 
Forward  0.9  1.0  1.4  1.2 
Clone # 1 
Forward  1.1  1.2  1.2  1.3 
Clone # 2 24 
4.5	  Total Protein Assay 
BSA standards were used to create a standard curve (Figure 4.) to determine 
the concentration of the total protein in the cell lysates. The total protein 
concentrations are reported in table 1. As noted in the previous section, the control 
cell lines contain almost two fold more total protein at the low levels of induction. 
This is likely due to the difference in growth between the controls and the clones. 
Total Protien Standard Curve for Cell 
Extracts 
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Figure 4. BSA Standard Curve 25 
4.6  t-PA Assay 
The original cell line was dilution cloned to assure homogeneity of the 
starting CHO cells before transfection. These cells were tested for t-PA activity to 
determine if the dilution clones varied in t-PA expression. Figure 5 shows nine of 
the clones t-PA activity. The top three producers were chosen to use for later 
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Figure 5. t-PA Activity of Dilution Clones. 26 
4.7  Glyoxalase I Assay 
The small sample size of the cell lysates limited the number of data sets that 
could be assayed. The glyoxalase I activity of the CHO and the clones under 
different levels of induction are listed in Table 2. All values are reported in units of 
specific activity ( Absorbance units/(min mg total protein ) ). 
Table 2.  Glyoxalase I activity. 
Cell line  0 .xM inducer  1 1.1.M  5 p.M  10 p.M 
CHO  0.4  0.5  0.6  0.6 
Forward  0.7  1.1  0.7  1.0 
Clone # 1 
Forward  1.0  1.5  1.9  0.9 
Clone # 2 
The data shows that the glyoxalase clones have roughly 2 to 3 fold higher 
levels of glyoxalase I activity. This activity data taken in conjunction with the protein 
gels supports the conclusion that the glyoxalase I clones are expressing higher levels 
of the enzyme then the CHO parent cell line. It is difficult to determine an optimal 27 
level of induction given this data, though it seems induction does have a slight effect. 
Further studies are needed to determine the best concentration of Ponasterone 
4.8  Methylglyoxal Assay 
Methylglyoxal levels were measured as described in Chapter 3. The forward 
orientation clone (glyoxalase I expressor) showed statistically significant 
(P =<0.001) lower levels of methylglyoxal (Statistical analyses by SigmaStat 2.0). 
Mean values are shown in the graph below. 
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Figure 6. Methylglyoxal Levels of Clones 28 
Chapter 5: Discussion 
The purpose of the research outlined in the previous chapters is to develop a model 
system to further study the toxic metabolite methylglyoxal. The hypothesis driving this 
model is the idea that methylglyoxal interferes with cell growth and productivity in industrial 
cell culture. As mentioned in Chapter 2 there is evidence to suggest that toxic metabolites 
interfere with the both the growth of cells and the quality of a recombinant product. 
Studies show endogenous methylglyoxal can have a negative effect on Chinese hamster 
ovary cells under batch conditions (Chap len et al., 1996a).  These results, taken in 
conjunction with studies that show unidentified low molecular weight inhibitory substances 
(Siwiora et al.  , 1994; Ronning et al., 1991) , warrant further investigation into methylglyoxal's 
inhibitory role. 
Several factors were taken into consideration in the development of the model. The 
CHO cell line was chosen because of its industrial relevance. CHO cells are commonly used 
to produce biopharmaceuticals in industry. In fact the CHO 1-155o, cell line used for this 
model is a precursor to the actual cell line used by Genentech to produce recombinant t-PA. 
In addition to this, earlier studies were done in CHO cells (Chaplen et al.  1996a), which 
make them a logical choice for continued investigations. 
The human glyoxalase I gene was chosen as the gene for overexpression because it is 
the principle detoxification enzyme for methylglyoxal. Earlier work used a bacterial 
glyoxalase I enzyme amplified under the dihydrofolate reductase (DHFR) system (Chaplen et 
al., 1996a). This amplification was not an option in the current system because DHFR gene 
was used for cloning the t-PA gene into the CHO cell line selected. Though in this case 29 
amplification should not be necessary because of the 10 to 20 greater binding affinity of the 
human enzyme (Thornalley, 1990). 
The expression system chosen was the Ecdysone-Inducible Expression  Kit from 
Invitrogen. This was chosen because of its inducible gene expression capabilities and 
because it utilized a different selection system than the CHO 1-15,  cell line. Briefly, the 
system is based on ability of the insect hormone 20 OH ecdysone to activate gene 
expression (No et al., 1996). The system is composed of two plasmids, pIND and pVgRXR. 
The pIND plasmid is the cloning vector and contains a multiple cloning site for use in 
creating various constructs. It also contains the ecdysone response elements upstream of a 
minimal heat shock promoter. These elements are bound by the retinoid X receptor 
expressed by the pVgRXR plasmid, which activates transcription of a gene cloned into the 
pIND multiple cloning site. The pIND plasmid contains the neomycin resistance gene and 
is selected for by the use of G418. The pVgRXR plasmid contains a Zeocin resistance gene 
and this antibiotic can be used in cells to select for plasmid integration. Since the retinoid X 
receptor will only bind the response elements in the presence of a ligand, such as 
ponasterone A, the system is inducible. 
While the kit reports that basal levels of transcription should be absent or low, the 
results from the glyoxalase I expressing clone shows induction only increases expression by 
2 fold at best. Basal levels of glyoxalase expression were approximately twice that of the 
CHO parent cell line. The implication of this is that it may not be necessary to induce these 
cells in order to study the effects of methylglyoxal. Though, further studies are needed to 
determine if expression can be increased with different amounts of inducer or with different 
lengths of induction. 30 
The product for the model cell line was chosen for several reasons. t-PA is a well 
characterized protein, many groups have looked at the effects of various conditions upon the 
quality of t-PA. These experiments are outlined in several papers (Kimura and Miller, 1997; 
Parekh et al., 1989; Lin et al., 1993).  t-PA also has both monoclonal and polyclonal 
antibodies commercially available, reducing the need for time consuming process of raising 
antibodies. This protein also has industrial relevance, as it was one of the first recombinant 
biopharmaceuticals produced in mammalian cell culture. The activity oft -PA depends on 
glycosylation and precise folding (Vehar et al., 1986). Other groups have shown that 
difference in glycosylation rates and sites effect t-PA activity (Kimura and Miller, 1997). 
Folding may be affected by methylglyoxal because of the dependence on intact cysteine 
residues for the formation of disulfide bonds. 
Also, t-PA contains a leader sequence which contains cysteine, lysine and arginine 
residues (Pennica et al., 1983). Methylglyoxal modification in this sequence could prevent 
leader sequence cleavage or interfere with protein transport. Degradation of t-PA results in 
formation of a two chain enzyme which is more susceptible to protease inhibitors (Kimura 
and Miller, 1997). Since methylglyoxal is known to target proteins for degradation, (Lo et al. 
1994) there may be a change in the ratio of one chain to two chain t-PA produced. There is 
interest in determining the effect of methylglyoxal modification in all of the above factors. 
While t-PA production has not yet been examined in the model cell lines, the assay 
developed in Section 3.9 will be useful in analyzing the activity of the clones. 
There is qualitative evidence to suggest that all three cell lines have slower growth 
rates than the parent cell line, a condition likely due to the increased burden of additional 
antibiotic selection. However, the most important thing is that the glyoxalase I clones have 
lower levels of methylglyoxal relative to the control clones, which will allow comparative 31 
studies under conditions approximating industrial cell culture. This is in fact the case as the 
glyoxalase I over-expresser demonstrates higher levels of glyoxalase I than the parent cell 
line and shows statistically significant lower levels of methylglyoxal than the two control cell 
lines. Future experiments should focus on the effect of methylglyoxal on the 
microheterogeniety oft -PA. The model system and associated controls (pIND and reverse 
orientation) represent ideal tools for addressing the question of whether methylglyoxal has a 
negative effect on specific productivity under industrial cell culture conditions. 32 
Chapter 6: Conclusions 
The model system developed here will be used to study the specific effects of 
methylglyoxal on cell growth, product yield and quality. Cell lines will be adapted to 
suspension culture and tested in conditions similar to those found in industrial cell culture. 
The impact of methylglyoxal on product quality will be determined through characterization 
studies of t-PA produced in control and glyoxalase I over-producing cell lines. t-PA yields 
can be determined through ELBA and western blot assays. Product quality analyses (peptide 
mapping) will compare the activity oft -PA produced in the control cell lines versus that of 
the t-PA produced with glyoxalase I over-expressing cell lines, which contain lower levels of 
methylglyoxal. 
The cell lines can also be used to further study the optimal media conditions that 
minimize methylglyoxal production. They can also be used to examine the role of 
methylglyoxal modification in protein processing and folding. Finally, it can be used to 
examine the effect of methylglyoxal on genetic drift and cell line stability. Overall, the cell 
lines will be a useful tool in further examining the impact of methylglyoxal on cell 
productivity. 33 
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Appendix  38 
Using pVgRXR, continued 
Map of pVgRXR  The figure below summarizes the features of pVgRXR. The complete nucleotide 
sequence for pVgRXR is available for downloading from our World Wide Web site 
(http://www.invitrogen.com) or by contacting Technical Service (see page 12). 
Comments for pVgRXR 
8803 nucleotides 
SV40 early promoter: bases 43-351  
EM7 promoter: bases 778-855  
Zeocinni resistance gene (Sh ble) ORF: bases 856-1230  
SV40 late polyadenylation sequence: base 1294-1424  
ColE1 orgin: bases 1533-2206  
CMV promoter: bases 2265-2883  
VP16/EcR fusion protein: bases 3035-5275  
VP16: bases 3038-3271  
EcR: bases 3302-5275  
HSV-1 thymidine kinase polyadenylation sequence: bases 5470-5982  
RSV 5' long terminal repeat: bases 6353-6614  
RXR ORF: bases 6637-8025  
BGH polyadenylation sequence: bases 8108-8332  
fl origin: bases 8502-8609  
continued on next page 39 
pIND, continued 
Map of pIND_  The figure below summarizes the features of the pIND vector. The complete nucleotide 
sequence for pIND is available for downloading from our World Wide Web site 
(http://www.invitrogen.com) or from Technical Service (see page 14). Details of the 
multiple cloning site are shown on page 6 for pIND. 
(1)  = -rs aC EXtt  0 (13  tti 
ct  'cC  CO C11 1-11 111 CO  >< sZ 
Comments for pIND 
5024 nucleotides 
Ecdysone/glucocorticoid 
Response Elements (5 x E/GREs): bases 1-174 
Heat Shock Minimal Promoter: bases 181-475 
Ecdysone Forward priming site: bases 429-452 
Multiple Cloning Site: bases 476-601 
pcDNA3.1/BGH Reverse priming site: bases 603-620 
BGH Polyadenylation sequence: bases 602-816 
fl origin: bases 879-1293 
SV40 promoter: bases 1357-1682 
SV40 ori6n: bases 1551-1636 
Neomycin ORF: bases 1718-2512 
SV40 Polyadenylation sequence: bases 2528-2767 
ColE I origin: bases 3199-3872 
Ampicillin ORF: bases 4017-4877 